Researchers led by Martin Fussenegger at ETH Zurich have developed an experimental electronic implant designed to treat type 2 diabetes without relying on insulin or traditional medications. Published in the journal Science, the study details a device that utilizes an electrically powered catalyst to transform excess blood glucose into gluconate, a substance the body eliminates through urine. This process aims to prevent surplus energy from being stored as fat, addressing a common issue where patients continue to gain weight despite insulin therapy.
Unlike previous attempts by the team that utilized engineered genetic networks and living cells, this new approach employs a catalyst made entirely of inorganic materials. The core of the implant consists of graphite felt covered with gold clusters and coated with platinum particles, creating a nanoscale surface capable of processing glucose without enzymes or biological components. This design addresses challenges related to immune compatibility, long-term stability, and regulatory approval often associated with biological treatments.
The system operates via a closed-loop control mechanism powered wirelessly at a frequency of 13.56 MHz. A conventional glucose sensor continuously monitors tissue glucose levels and communicates with a smartphone or smartwatch via Bluetooth. When blood sugar rises, such as after a meal, the connected device activates the implant to supply the electrical energy needed for the catalyst to function. Once glucose levels return to the desired range, the system automatically shuts down to prevent dangerously low blood sugar.
Initial laboratory tests using a 5-liter nutrient solution, equivalent to the blood volume of an adult human, confirmed the catalyst's ability to convert glucose on a relevant scale. Subsequent trials in diabetic mice over six weeks showed that the implant could precisely regulate blood sugar levels while promoting weight loss. The device operated at low voltage with no evidence of tissue damage from electrical or thermal effects, and it was well tolerated by the animals.
Fussenegger notes that this technology represents a fundamental shift in diabetes management, moving from influencing how the body processes glucose to directly controlling glucose availability using electronics. While the findings are promising, the device has not yet been tested in humans. The researchers' next objective is to advance the experimental implant into a medical device suitable for further development and eventual clinical trials, potentially leveraging existing digital health systems and wireless power technologies.
Sources: ScienceDaily.